Stent versus bypass for femoropopliteal TASC II Type C and D lesions: a prospective randomised trial

Paracelsus Medical University (PMU)0 个研究点目标入组 218 人开始时间: 2016年4月29日最近更新: 2024年5月21日

适应症

试验速览

2019 Results article in https://pubmed.ncbi.nlm.nih.gov/31786218/ 2-year results (added 12/08/2022) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35185122/ 4-year results (added 12/08/2022) 2023 Results article in https://doi.org/10.3390/jcm12103507 Long-Term Outcome of Bypass Surgery versus Endovascular Revascularization in Long Femoropopliteal Lesions (added 10/05/2024) 2022 Results article in https://doi.org/10.3390/medicina58091225 Long-Term Results of Endovascular Treatment with Nitinol Stents for Femoropopliteal TASC II C and D Lesions (added 10/05/2024)

•1. Aged 30 years and over
•2. Peripheral arterial occlusive disease of the lower extremity due to atherosclerosis
•3. Disabling claudication (walking distance < 200 m) or critical ischemia (rest pain and/or tissue loss)
•4. Radiologically verified long lesions (TASC II Type C or D) of the femoral and/or politeal artery
•5. Symptoms for more than 2 months
•6. Unimpaired ipsilateral iliac arteries
•7. Capacity to provide informed consent

•1. Acute ischemia
•2. Embolic occlusion of the femoropopliteal segment
•4. Non-disabling claudication (walking distance > 200 m)
•5. Radiologically verified short femoropopliteal lesions (TASC II Type A and B)
•6. Vasculitis
•7. Renal insufficiency (glomerular filtration rate < 45 ml/min/1.73 m2)
•8. No informed consent
•9. Pregnancy
•10. Patient too frail for bypass surgery: American Society of Anesthesiologists (ASA) - Class >3

发起方

Paracelsus Medical University (PMU)